Sapu Nano Platform Broadens Hydrophobic Drug Formulation Capabilities

Event summary

  • Oncotelic Therapeutics’ 45% joint venture, Sapu Nano, unveiled data at the 2025 San Antonio Breast Cancer Symposium demonstrating its Deciparticle™ nanomedicine platform’s broad formulation capabilities.
  • The platform successfully encapsulates multiple classes of hydrophobic drugs, including macrolide mTOR inhibitors (Sirolimus, Temsirolimus, Ridaforolimus, Umirolimus, Everolimus), ascomycin macrolactams (Tacrolimus), and peptides (Cyclosporine A, Exenatide).
  • Sapu Nano operates an ISO-5 cGMP facility enabling one-pot drug manufacturing, sterile filtration, automated fill/finish, and lyophilization.
  • The Deciparticle™ platform maintains a consistent sub-20 nm nanoparticle profile suitable for intravenous delivery.

The big picture

Sapu Nano’s Deciparticle™ platform represents a significant advancement in nanomedicine, addressing a longstanding challenge in formulating hydrophobic drugs. This technology could unlock the therapeutic potential of a wide range of previously undruggable compounds, potentially expanding the pipeline for both oncology and immunology applications. The platform's cGMP-ready manufacturing capabilities suggest a faster path to market compared to traditional drug development, but success hinges on clinical validation and regulatory acceptance.

What we're watching

Commercialization
The platform's ability to support multiple INDs annually will be a key indicator of its commercial viability and potential revenue generation for both Oncotelic and Sapu Nano.
Platform Limits
The observation that Pimecrolimus exceeded the Deciparticle™ threshold highlights a potential constraint on the platform's applicability and requires further investigation into design modifications.
Regulatory Approval
The cGMP-readiness of the platform is a positive, but successful translation to regulatory approval for formulated drugs will depend on demonstrating consistent quality and efficacy in clinical trials.

Related topics

Pharmaceuticals Biotechnology